Month: May 2021

Candel Therapeutics at the Jefferies Virtual Healthcare Conference 2021

Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, M.D. Ph.D., President and Chief Executive Officer, will present an overview of the Company at the upcoming Jefferies Virtual Healthcare Conference in June 2021.

About Candel Therapeutics

Candel is dedicated to assisting patients in their battle against cancer through oncolytic viral immunotherapies. Our specially engineered viruses are crafted to trigger immunogenic cell death by directly attacking cancer cells, thereby releasing tumor neo-antigens and fostering a pro-inflammatory microenvironment at the injection site. Our strategy integrates a profound understanding of viral immunotherapy with extensive clinical expertise spanning various indications. Drawing from the wealth of data derived from our preclinical models and clinical trials employing our methodology, we have identified what we interpret as a systemic immune response targeting both locally injected tumors and their distant metastases. To learn more, visit

View Article:

Carrie Cox joins the Candel team and lead our Board of Directors

We are delighted to have Carrie Cox join the Candel team and lead our Board of Directors. Her strategic insights will be key as we advance our late stage pipeline of agents with the potential to become important medicines for patients with cancer.

Who are Candel Therapeutics?

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Our engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Our approach combines an in-depth knowledge of viral immunotherapy with extensive clinical experience across a wide range of indications. Based on the broad range of data that we have generated from our preclinical models and clinical trials using our approach, we have observed what we believe to be a systemic immune response against locally injected tumors and their distant metastases.

Candel today announced that Carrie S. Cox has been named Chairman of the Board of Directors, effective immediately. Paul Manning, the outgoing Chairman, will continue to serve as a Director.

Who is Carrie Cox?

Ms. Cox has had an eminent career in the biopharmaceutical industry, both in operating roles and as a corporate director. She is currently the Chairman of Organon, a women’s health spinoff of Merck & Co. She was also recently the Chairman of Array Biopharma, which was acquired by Pfizer for $11.4 billion in 2019, as well as a Director on the Board of Celgene, which was acquired by Bristol Myers Squibb in a $74 billion transaction. Prior to her numerous board roles, she served as Executive Vice President and President of Schering-Plough’s Global Pharmaceutical Business, which generated approximately $16 billion in annual sales driven by an annual growth rate of 22%.

“I am grateful to Paul for his extraordinary support and the guidance he has provided in building Candel into what it is today and we look forward to his continued, deep involvement as a valued member of our Board of Directors,” said Paul Peter Tak, President and Chief Executive Officer of Candel. “We are all delighted to have Carrie join the Candel team and lead our Board of Directors. Her strategic insights will be key as we advance our late stage pipeline of agents with the potential to become important medicines for patients with cancer.”

Mr. Manning added, “I am thrilled with the progress that the Candel team has made under Paul Peter’s leadership and I look forward to continuing to work with and support the Candel team. Ms. Cox is an experienced pharmaceutical leader with an exceptional history of success. She is the ideal choice to lead our Board as Candel advances into the next phase of the company’s trajectory.”

Ms. Cox further commented, “I am proud to join Candel’s Board at this exciting time in the company’s growth. Candel has a rich pipeline of innovative oncolytic viral immunotherapies and I look forward to working closely with Candel’s management and my colleagues on the Board to progress these programs with such promise to benefit patients.”

Carrie Cox’s Achievements

Ms. Cox currently serves on the Boards of Directors of Organon, Cardinal Health, Selecta BioSciences, and Texas Instruments. Ms. Cox previously served as Chairman and Chief Executive Officer of Humacyte, Inc., which she joined in 2010. Ms. Cox also served as Chairman of Prism Pharmaceuticals, sold to Baxter Corporation in 2011. Ms. Cox spent her early career at Sandoz Pharmaceuticals (now Novartis) in a variety of commercial roles. She was later President of Global Prescription Business at Pharmacia Corporation, Senior Vice President of Global Business Management at Pharmacia & Upjohn, as well as Vice President of Women’s Healthcare at Wyeth-Ayerst (all now Pfizer).

Fortune magazine named Ms. Cox to its List of the “50 Most Powerful Women in Business” six times. She is a graduate of the Massachusetts College of Pharmacy and Health Sciences.

View Article:

Prof Paul Peter Tak: Rheumatology, Real Impact and Comfort Zones

In this week’s podcast episode, Professor Paul Peter Tak joins us as we delve into the multifaceted facets of his life, starting from his formative years growing up in the Netherlands. Professor Tak shares insights into his captivating medical career, tracing the unique trajectory that led him to specialize in Rheumatology, a field where he has become a trailblazing figure. Our conversation unfolds to explore the intricacies of his illustrious career in Rheumatology research, shedding light on the profound contributions he has made to the field. As we navigate through the milestones of his professional journey, Professor Tak opens up about his unwavering commitment to making a tangible impact on the lives of patients. This episode provides a comprehensive and in-depth look into the life, career, and aspirations of Professor Paul Peter Tak, offering listeners a unique opportunity to gain a nuanced understanding of his remarkable experiences and the transformative influence he seeks to wield in the realm of medical research and patient care.

Listen to the podcast:

The Story of Flagship Pioneering and The Future of Medicines

James is delighted to be joined by the accomplished Dr. Paul-Peter Tak, currently serving as the Venture Partner at Flagship Pioneering and holding the esteemed position of CEO at Kintai Therapeutics. Dr. Tak boasts an impressive career spanning more than 25 years in the life sciences sector, during which he has played instrumental roles in creating and leading multiple companies. Notably, from 2011 to 2017, Dr. Tak served as the founder and senior vice president, heading the immuno-inflammation therapy area unit at GSK. His leadership during this period resulted in the introduction of over 10 new mechanisms of action into clinical trials, marking a significant contribution to the field. Subsequently, from 2016 to 2018, Dr. Tak assumed key roles as senior vice president of R&D pipeline, chief immunology officer, development leader, and co-chair of GSK’s scientific review board. In these capacities, he oversaw the strategic development of a ground-breaking portfolio of medicines in oncology, with a specific focus on immuno-oncology, epigenetics, and cell and gene therapy. This extensive and impactful journey in the life sciences positions Dr. Paul-Peter Tak as a distinguished figure in the industry, and his insights promise to provide a wealth of knowledge on the podcast.

Listen to the podcast:

Careers in Discovery

Embark on an enriching exploration into the dynamic realms of Pharma and Biotech with “Careers in Discovery” – a captivating series that serves as your exclusive window into the captivating world of Drug Discovery and Research & Development (R&D). Tune in every week for in-depth interviews with trailblazing leaders in these fields, gaining unparalleled insights into their illustrious careers. Discover the transformative work they are engaged in, unravel the fascinating stories of their professional journeys, understand the pivotal moments that shaped their trajectories, and unearth the valuable advice they would bestow upon their younger selves. This illuminating series, brought to you by the industry-driven expertise of Singular Talent (, provides an invaluable resource for anyone aspiring to carve a niche in the ever-evolving landscape of pharmaceutical and biotechnological advancements. Join us on this inspiring journey, where each episode unveils the multifaceted tapestry of careers in discovery, offering a comprehensive and nuanced perspective on the diverse avenues within these dynamic industries.

Listen to the podcast:

Listen Notes: Paul-Peter Tak, Academic, business leader and biotech entrepreneur

In this engaging episode, Dr. Paul-Peter Tak joins Monica Westley for an insightful conversation delving into his innovative ideas within the realm of type 1 diabetes. As an esteemed immunologist, academic, and venture partner with a specialization in rheumatology and immunology, Dr. Tak brings a wealth of expertise to the discussion. Together, they explore the intriguing intersection of immunology and the quest for a cure for T1D. Dr. Tak shares his forward-thinking perspective on reclassifying type 1 diabetes. Through his unique lens as an immunologist, he envisions a transformative future that involves a paradigm shift in understanding and approaching the complexities of T1D. Tune in to gain deeper insights into Dr. Tak’s visionary thoughts on the future landscape of type 1 diabetes research and the pivotal role that immunology can play in unlocking new possibilities for a cure.

Paul-Peter Tak- “I think the future is clearly in looking at type 1 diabetes in a different way. I would almost reclassify it (as an immunologist, not necessarily as a diabetes expert) and I would call it pancreatic autoimmunity.” 

Listen to the podcast:

EXCLUSIVE: Flagship Pioneering Company Kintai Therapeutics Focuses on Enteric Therapeutics

The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessing the gut could drive more promising drug development has led to the formation of a new company, Kintai Therapeutics.

View article:

  • 1
  • 2
Paul Peter Tak

© Paul Peter Tak.
All rights reserved.